Topic Highlight
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Nov 14, 2013; 19(42): 7302-7307
Published online Nov 14, 2013. doi: 10.3748/wjg.v19.i42.7302
Pharmacological challenges in chronic pancreatitis
Anne Estrup Olesen, Anne Brokjaer, Iben Wendelboe Fisher, Isabelle Myriam Larsen
Anne Estrup Olesen, Anne Brokjaer, Iben Wendelboe Fisher, Isabelle Myriam Larsen, Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, 9000 Aalborg, Denmark
Anne Brokjaer, Center for Sensory-Motor Interaction, Department of Health Science and Technology, Aalborg University, 9000 Aalborg, Denmark
Iben Wendelboe Fisher, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, 1455 Copenhagen, Denmark
Author contributions: All authors contributed to this review.
Supported by The Danish Council for Strategic Research
Correspondence to: Anne Estrup Olesen, MSc (pharm), PhD, Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Mølleparkvej 4, 9000 Aalborg, Denmark. aneso@rn.dk
Telephone: +45-99-326246 Fax: +45-99-326507
Received: June 19, 2013
Revised: October 2, 2013
Accepted: October 19, 2013
Published online: November 14, 2013
Processing time: 151 Days and 17.5 Hours
Core Tip

Core tip: In patients with chronic pancreatitis several pathophysiological factors can account for malabsorption and may also affect the efficacy of pharmacological intervention by reduced drug absorption. For example it can be speculated that changes in gastrointestinal intraluminal pH, motility disorder, bacterial overgrowth and changed pancreatic gland secretion may contribute. The lifestyle of chronic pancreatitis patients may also be a factor to gastrointestinal changes. The factors may not have clinical relevance, but may explain inter-individual variations in responses to a given drug, in patients with chronic pancreatitis.